Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
IMNP is in the long-term down -100% below S&P in 3 years.
Description: Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer. Its lead product candidate includes Bertilimumab, a human monoclonal antibody that is under Phase II clinical trial for the treatment of ulcerative colitis, as well as for the treatment of bullous pemphigoid, Crohn's disease, and severe asthma. The company?s product pipeline also comprise AmiKet, a topical analgesic cream for the treatment of peripheral neuropathies that is under Phase III clinical trials; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with solid tumors, which is under Phase I/II clinical trials. In addition, its preclinical stage product candidate includes anti-ferritin combination gemcitabine-paclitaxel NanomAbs for the treatment of pancreatic and non-small cell lung cancer. Immune Pharmaceuticals, Inc. has strategic partn
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-63.26%||ROE||-144.78%||ROI|
|Current Ratio||0.56||Quick Ratio||Long Term Debt/Equity||-0.43||Debt Ratio||0.49|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||-460 K||Cash From Investing Activities||-50 K||Cash From Operating Activities||-2.25 M||Gross Profit|
|Net Profit||-3.56 M||Operating Profit||-3.45 M||Total Assets||35.3 M||Total Current Assets||4.26 M|
|Total Current Liabilities||7.57 M||Total Debt||3.09 M||Total Liabilities||19.87 M||Total Revenue|
|High 52 week||0.83||Low 52 week||0.02||Last close||0.02||Last change||0%|
|RSI||30.8||Average true range||Beta||0.68||Volume||4.1 M|
|Simple moving average 20 days||-39.61%||Simple moving average 50 days||-59.37%||Simple moving average 200 days||-91.29%|
|Performance Week||-18.92%||Performance Month||-50%||Performance Quart||-79.73%||Performance Half||-92.89%|
|Performance Year||-97.89%||Performance Year-to-date||-97.37%||Volatility daily||17.83%||Volatility weekly||39.88%|
|Volatility monthly||81.72%||Volatility yearly||283.1%||Relative Volume||67.16%||Average Volume||507.38 K|
|New High||New Low|
2019-02-19 07:38:54 | Immune Pharmaceuticals Files for Chapter 11 Protection
2018-12-06 09:00:00 | Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders
2018-11-19 17:53:42 | Immune Pharmaceuticals Reschedules Corporate Update Call
2018-11-16 08:30:00 | Immune Pharmaceuticals Schedules Corporate Update Call
2018-10-29 07:50:00 | Report: Developing Opportunities within Strategic Education, Semtech, Immune Pharmaceuticals, American Renal Associates, Thor Industries, and American Woodmark — Future Expectations, Projections Moving into 2018
2018-10-29 07:30:00 | New Clinical Data Support Bertilimumab Activity in Bullous Pemphigoid
2018-10-17 09:00:00 | Immune Pharmaceuticals Announces Positive Preclinical Results in Asthma
2018-10-10 16:30:00 | Immune Pharmaceuticals Announces $5 Million Financing
2018-09-13 07:30:00 | Immune Pharmaceuticals Provides a Corporate Update
2018-09-11 07:30:00 | Bertilimumab Granted Fast Track Designation for the Treatment of Bullous Pemphigoid
2018-09-10 07:00:00 | Immune Pharmaceuticals Issues Statement on Former Chief Executive Officer
2018-08-20 11:34:13 | Bertilimumab Granted Orphan Drug Designation for the Treatment of Bullous Pemphigoid
2018-08-02 16:05:00 | Immune Pharmaceuticals Postpones Special Meeting of Stockholders
2018-07-17 08:30:00 | Immune Pharmaceuticals Announces Filing of Proxy Statement for Reverse Stock Split
2018-07-06 07:55:00 | Free Pre-Market Technical Recap on Sanofi and Three Additional Drug Makers Stocks
2018-06-25 08:25:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Immune Pharmaceuticals, Wells Fargo, Anadarko Petroleum, CTS, REGENXBIO, and TripAdvisor — New Research Emphasizes Economic Growth
2018-06-08 08:30:00 | Immune Pharmaceuticals Announces Receipt of Nasdaq Listing Determination
2018-06-04 13:14:21 | Breakeven On The Horizon For Immune Pharmaceuticals Inc NASDAQ:IMNP
2018-05-24 15:15:22 | Is Immune Pharmaceuticals Inc NASDAQ:IMNP An Industry Laggard Or Leader?
2018-05-23 08:00:00 | Immune Pharmaceuticals Provides a Pipeline Update
2018-05-07 08:30:00 | Immune Pharmaceuticals Provides Update on Plans for Oncology Subsidiary, Cytovia, Inc.
2018-05-07 08:25:00 | Market Trends Toward New Normal in The AES, Immune Pharmaceuticals, Hercules Capital, Zendesk, Chevron, and Cornerstone OnDemand — Emerging Consolidated Expectations, Analyst Ratings
2018-04-02 17:20:00 | Immune Pharmaceuticals Announces 2017 Financial Results
2018-03-12 12:46:11 | Interested In Immune Pharmaceuticals Inc NASDAQ:IMNP? Here’s How It Performed Recently
2018-03-05 08:15:00 | Research Report Identifies CarGurus, Peabody Energy, Brighthouse Financial, CPI Card Group, Alcoa, and Immune Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
2018-03-02 13:07:21 | Immune Pharmaceuticals Inc’s NASDAQ:IMNP Profit Outlook
2018-02-27 08:00:00 | Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders
2018-01-26 08:00:00 | Immune Pharmaceuticals Announces Adjournment of Annual Meeting
2018-01-06 13:30:30 | What Are The Drivers Of Immune Pharmaceuticals Inc’s NASDAQ:IMNP Risks?
2017-12-14 14:05:09 | Is Immune Pharmaceuticals Inc’s NASDAQ:IMNP CEO Salary Justified?
2017-12-05 12:35:08 | Does Immune Pharmaceuticals Inc’s IMNP Past Performance Indicate A Stronger Future?
2017-11-04 19:29:11 | Should You Invest In The Healthcare Stock Immune Pharmaceuticals Inc IMNP?